Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy
Keli An, Yuan Li, Chunyu Cao, Ming Wang, Xiaohui Jia, Guorui Jin, Bo Cheng, Yuanbo Jia, Lin Wang, Hui Guo, Feng Xu, Kai Qu · 2026
Read Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy by Keli An, Yuan Li, Chunyu Cao, Ming Wang, Xiaohui Jia, Guorui Jin, Bo Cheng, Yuanbo Jia, Lin Wang, Hui Guo, Feng Xu, Kai Qu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13292261.txt.
Description
Keli An and co-authors design a 2026 cancer drug that wakes up only where tumors run low on oxygen. Their molecule, hrFP-E, is a PROTAC carrying two warheads: one destroys focal adhesion kinase, a protein tied to stiff tissue and invasion, and the other blocks EGFR growth signaling. A nitroreductase-sensitive switch keeps it inert until it reaches hypoxic zones.
In lung cancer models, the activated drug wiped out roughly 96 to 99 percent of the target kinase and suppressed EGFR signaling by about 88 percent of its starting level. Combined effects slowed cell movement and growth in flat and 3D cultures. In animals, tumors shrank by about 66 percent of expected growth without obvious toxicity, and tissue grew softer and less collagen-dense. The authors pitch the design as a modular mechano-chemical platform.
Catalog record
| CREATOR | Keli An, Yuan Li, Chunyu Cao, Ming Wang, Xiaohui Jia, Guorui Jin, Bo Cheng, Yuanbo Jia, Lin Wang, Hui Guo, Feng Xu, Kai Qu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56590 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |